Details
Stereochemistry | ACHIRAL |
Molecular Formula | C23H25ClFN7O |
Molecular Weight | 469.942 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC(NC2=NN3C(CC4=C(F)C=C(Cl)C=C4)=C(C)N=C3C(CN5CCOCC5)=C2)=NN1
InChI
InChIKey=SQSZANZGUXWJEA-UHFFFAOYSA-N
InChI=1S/C23H25ClFN7O/c1-14-9-21(29-28-14)27-22-11-17(13-31-5-7-33-8-6-31)23-26-15(2)20(32(23)30-22)10-16-3-4-18(24)12-19(16)25/h3-4,9,11-12H,5-8,10,13H2,1-2H3,(H2,27,28,29,30)
DescriptionCurator's Comment: description was created based on several sources, including:
http://www.pharmacodia.com/yaodu/html/v1/chemicals/6eab78f10219a83895b2e2d71dc0656e.html | https://www.ncbi.nlm.nih.gov/pubmed/23317159 | https://www.ncbi.nlm.nih.gov/pubmed/22227528
Curator's Comment: description was created based on several sources, including:
http://www.pharmacodia.com/yaodu/html/v1/chemicals/6eab78f10219a83895b2e2d71dc0656e.html | https://www.ncbi.nlm.nih.gov/pubmed/23317159 | https://www.ncbi.nlm.nih.gov/pubmed/22227528
An orally bioavailable imidazopyridazine and inhibitor of Janus kinase 2 mutant V617F (JAK2V617F), with potential antineoplastic activity. Upon oral administration, gandotinib selectively and competitively inhibits the activation of JAK2V617F, which may result in the inhibition of the JAK-STAT signaling pathway and the induction of apoptosis in JAK2V617F-expressing tumor cells. Gandotinib is in phase II clinical trials by Lilly for the treatment of myeloproliferative disorders.
Originator
Sources: http://adisinsight.springer.com/drugs/800032290
Curator's Comment: # Eli Lilly
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2971 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22227528 |
0.055 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01594723
120 mg administered once daily for 6 cycles (168 days).
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23584399
LY2784544 effectively inhibited JAK2V617F-driven signaling and cell proliferation in Ba/F3 cells (IC50=20 and 55 nM, respectively). In comparison, LY2784544 was much less potent at inhibiting interleukin-3-stimulated wild-type JAK2-mediated signaling and cell proliferation (IC50=1183 and 1309 nM, respectively).
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
334211
Created by
admin on Sat Dec 16 15:52:34 GMT 2023 , Edited by admin on Sat Dec 16 15:52:34 GMT 2023
|
||
|
NCI_THESAURUS |
C1967
Created by
admin on Sat Dec 16 15:52:34 GMT 2023 , Edited by admin on Sat Dec 16 15:52:34 GMT 2023
|
||
|
NCI_THESAURUS |
C129825
Created by
admin on Sat Dec 16 15:52:34 GMT 2023 , Edited by admin on Sat Dec 16 15:52:34 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL2107823
Created by
admin on Sat Dec 16 15:52:34 GMT 2023 , Edited by admin on Sat Dec 16 15:52:34 GMT 2023
|
PRIMARY | |||
|
SUB128915
Created by
admin on Sat Dec 16 15:52:34 GMT 2023 , Edited by admin on Sat Dec 16 15:52:34 GMT 2023
|
PRIMARY | |||
|
ANC71R916O
Created by
admin on Sat Dec 16 15:52:34 GMT 2023 , Edited by admin on Sat Dec 16 15:52:34 GMT 2023
|
PRIMARY | |||
|
Gandotinib
Created by
admin on Sat Dec 16 15:52:34 GMT 2023 , Edited by admin on Sat Dec 16 15:52:34 GMT 2023
|
PRIMARY | |||
|
ZZ-54
Created by
admin on Sat Dec 16 15:52:34 GMT 2023 , Edited by admin on Sat Dec 16 15:52:34 GMT 2023
|
PRIMARY | |||
|
DB13040
Created by
admin on Sat Dec 16 15:52:34 GMT 2023 , Edited by admin on Sat Dec 16 15:52:34 GMT 2023
|
PRIMARY | |||
|
100000155073
Created by
admin on Sat Dec 16 15:52:34 GMT 2023 , Edited by admin on Sat Dec 16 15:52:34 GMT 2023
|
PRIMARY | |||
|
C116857
Created by
admin on Sat Dec 16 15:52:34 GMT 2023 , Edited by admin on Sat Dec 16 15:52:34 GMT 2023
|
PRIMARY | |||
|
9695
Created by
admin on Sat Dec 16 15:52:34 GMT 2023 , Edited by admin on Sat Dec 16 15:52:34 GMT 2023
|
PRIMARY | |||
|
DTXSID20153789
Created by
admin on Sat Dec 16 15:52:34 GMT 2023 , Edited by admin on Sat Dec 16 15:52:34 GMT 2023
|
PRIMARY | |||
|
46213929
Created by
admin on Sat Dec 16 15:52:34 GMT 2023 , Edited by admin on Sat Dec 16 15:52:34 GMT 2023
|
PRIMARY | |||
|
1229236-86-5
Created by
admin on Sat Dec 16 15:52:34 GMT 2023 , Edited by admin on Sat Dec 16 15:52:34 GMT 2023
|
PRIMARY |
ACTIVE MOIETY